Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.takesolutions.com | |
Market Cap | 356.52 Cr. | |
Enterprise Value(EV) | 765.01 Cr. | 2021-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | -8.25 | Trailing Twelve Months Ending 2021-12 |
Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2021-12 |
Industry PE | 27.39 | Trailing Twelve Months Ending 2021-12 |
Book Value / Share | 71.67 | Trailing Twelve Months Ending 2021-12 |
Price to Book Value | 0.34 | Calculated using Price: 24.10 |
Dividend Yield | 0.00 | Period Ending 2021-03 |
No. of Shares Subscribed | 14.79 Cr. | 147,934,000 Shares |
FaceValue | 1 | |
Company Profile | ||
TAKE Solutions is a globally-recognized domain-leader in Life Sciences and Supply Chain Management. TAKE leverages its domain expertise, innovation-driven technology, best practices and people strength to offer clients transformative full services across clinical development, and point services in supply chain. In the fast-growing Life Sciences space, TAKE offers clients a unique combination of full-service Clinical, Regulatory and Safety services backed by unique technology expertise. Its range of services span from clinical trials to regulatory submissions to post-marketing safety, all backed by insights derived through proprietary industry networks forums. With a team of leading Life Sciences experts, best-in-class systems and processes, and bespoke, industry-specific technology and analytics, TAKE delivers successful outcomes for clients. Its global roster of clients includes large and small innovator biopharmaceutical companies as well as generics manufacturers. In Supply Chain Management, TAKE focuses on high-margin niches in engineering services, and supply chain collaboration. Its IP-led approach enables its clients to automate supply chain processes, track, trace & control at item level, mandate supplier compliance, and streamline material & shipment movement, and thus optimize their processes. With operations spread across North America, Europe, Asia, and South America, TAKE is a Public Company, listed in India on the Bombay Stock Exchange and the National Stock Exchange. Business area of the company The company delivers domain-intensive services in Life Sciences and Supply Chain Management. The company offers clients a unique combination of full service Clinical, Regulatory and Safety services with unique technology expertise. The Company's services span clinical trials to regulatory submissions to post-marketing strategy with insights derived through proprietary industry network forums. Products and services Life Sciences:
Supply Chain Management:
Company’s technology products and solutions are:
Awards
Milestones 2000-2004
2007-2010
2011-2014
2015
2016
2017
2018
2019-20
|
1 Day |
|
+1.69% |
1 Week |
|
+8.56% |
1 Month |
|
-20.72% |
3 Month |
|
-31.44% |
6 Month |
|
-48.12% |
1 Year |
|
-65.15% |
2 Year |
|
-52.70% |
5 Year |
|
-81.60% |
10 Year |
|
-17.61% |
9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
Return on Equity (%) | 23.38 | 13.88 | 16.08 | 21.61 | 19.05 | 14.37 | 12.61 | -0.71 | -33.61 | |
Return on Capital Employed (%) | 21.14 | 11.84 | 13.91 | 18.78 | 17.74 | 14.91 | 13.21 | 1.38 | -21.14 | |
Return on Assets (%) | 11.30 | 7.27 | 8.96 | 11.69 | 11.32 | 9.96 | 8.55 | -0.46 | -20.98 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-09* Rs. Cr. |
Shh. Funds | 420 | 470 | 524 | 631 | 911 | 1,328 | 1,518 | 1,575 | 1,125 | 1,117 | |
Non Curr. Liab. | 113 | 82 | 26 | 99 | 81 | 89 | 80 | 219 | 178 | 151 | |
Curr. Liab. | 258 | 262 | 316 | 443 | 336 | 415 | 724 | 660 | 524 | 571 | |
Minority Int. | 46 | 48 | 56 | 40 | 42 | 8 | 9 | 10 | 0 | 0 | |
Equity & Liab. | 837 | 862 | 922 | 1,214 | 1,369 | 1,840 | 2,331 | 2,464 | 1,826 | 1,838 | |
Non Curr. Assets | 376 | 401 | 397 | 587 | 590 | 662 | 1,159 | 1,266 | 965 | 956 | |
Curr. Assets | 460 | 461 | 525 | 626 | 779 | 1,178 | 1,172 | 1,199 | 861 | 882 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 837 | 862 | 922 | 1,214 | 1,369 | 1,840 | 2,331 | 2,464 | 1,826 | 1,838 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-12 Rs. Cr. TTM |
Net Sales | 832 | 816 | 730 | 1,030 | 1,345 | 1,587 | 2,039 | 2,213 | 777 | 835 | |
Other Income | 7 | 6 | 8 | 21 | 13 | 6 | 11 | 26 | 12 | 14 | |
Total Income | 839 | 822 | 739 | 1,051 | 1,357 | 1,594 | 2,050 | 2,239 | 789 | 849 | |
Total Expenditure | -671 | -668 | -620 | -866 | -1,082 | -1,281 | -1,656 | -2,044 | -847 | -756 | |
PBIDT | 168 | 153 | 118 | 185 | 275 | 313 | 394 | 195 | -58 | 94 | |
Interest | -14 | -14 | -13 | -15 | -23 | -21 | -25 | -41 | -37 | -36 | |
Depreciation | -46 | -77 | -20 | -25 | -87 | -104 | -154 | -167 | -115 | -102 | |
Taxation | -18 | -1 | -5 | -20 | -19 | -28 | -37 | 2 | -14 | -10 | |
Exceptional Items | -225 | -68 | |||||||||
PAT | 89 | 62 | 80 | 125 | 146 | 160 | 178 | -11 | -450 | -122 | |
Minority Interest | -10 | -4 | -10 | -5 | -3 | 1 | -1 | -1 | -2 | 0 | |
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 79 | 58 | 70 | 120 | 143 | 160 | 177 | -12 | -452 | -122 | |
Adjusted EPS | 7 | 5 | 6 | 10 | 11 | 11 | 12 | -1 | -31 | -8 |
Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
Cash Fr. Operatn. | 115 | 117 | 100 | 74 | 148 | 56 | 121 | 104 | 211 | 135 | |
Cash Fr. Inv. | -81 | -70 | -91 | -16 | -257 | -129 | -179 | -485 | -236 | -57 | |
Cash Fr. Finan. | -21 | -31 | -7 | -11 | 114 | 56 | 302 | 100 | 21 | -84 | |
Net Change | 13 | 16 | 2 | 46 | 5 | -17 | 244 | -281 | -4 | -6 | |
Cash & Cash Eqvt | 54 | 70 | 72 | 121 | 91 | 74 | 317 | 47 | 45 | 39 |
Fri, 20 May 2022
Board Meeting Intimation for Notice Of Board Meeting TAKE SOLUTIONS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2022 inter alia to consider and approve the Audited Financial results for the fourth quarter and financial year ended March 31 2022. |
Fri, 13 May 2022
Re-Appointment Of Independent Director Of The Company This is to inform that the Board of Directors of the Company in its meeting held on Friday May 13 2022 approved the re-appointment of Mr. Venkataraman Murali as an Independent Director of the Company with effect from 18th May 2022 for a period of five years subject to approval of the Shareholders. |
Sat, 07 May 2022
Intimation Of Action By Deloitte & Touche LLP (Receivers) Dated 6Th May 2022 With Respect To Shares Held By TAKE Solutions Ltd ('The Company') In TAKE Solutions Global Holdings Pte Ltd Singapore Under Regulation 30 Of The SEBI (LODR) Regulations 2015 Read With SEBI Circular CIR/CFD/CMD/4/2015 Dated September 09 2015. Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circular CIR/CFD/CMD/4/2015 dated September 09 2015 regarding intimation of action by Deloitte & Touche LLP (Receivers) dated 6th May 2022 with respect to Shares held by TAKE Solutions Ltd (the Company) in TAKE Solutions Global Holdings Pte Ltd Singapore is enclosed herewith. |
Fri, 20 May 2022 |
|
|
|
|
|